Cell Bio Human Tech Completes 5 Billion Won Treasury Stock Acquisition via Trust, Enhancing Shareholder Value

Cell Bio Human Tech acquired 74,956 common shares through a trust contract with Daishin Securities from April 14 to June 9, 2026, holding them as treasury shares.
The total acquisition amount was approximately 500 million KRW, consuming 99.94% of the trust contract amount of 500 million KRW, representing 0.80% of total outstanding shares of 9,337,513.
The largest shareholder Lee Kwon-sun increased his holdings from 3,217,065 to 3,236,521 shares through open market purchases as of the report date.
The trust contract was terminated on June 9, 2026, within three months of the initial contract date, and the report on termination was submitted.
[AI Summary]This report confirms the completion of a small-scale treasury stock acquisition. With a buyback ratio below 1%, the direct impact on stock price is limited, but the intention to stabilize the stock price through buybacks can be viewed positively. The increase in the largest shareholder's stake contributes to management stability.